SCHEMBL4130897

SCHEMBL4130897

C[C@@H]1CCc2ccccc2N1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.45
BRD4 O60885 4/20 0.43
CREBBP Q92793 3/20 0.43
EP300 Q09472 1/20 0.43
SMYD3 Q9H7B4 1/20 0.41
NPC1 O15118 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.38
PDPK1 O15530 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734662 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL29683355 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL424121 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL29641564 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
Ammonia Solution, Strong SCHEMBL5054545 0.98 MTNR1A (0.44) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL166058 0.88 MAPT (0.43) MTNR1ABRD4CREBBPEP300NPC1
SCHEMBL23812633 0.85 TSHR (0.41) MTNR1ABRD4CREBBPEP300NPC1
SCHEMBL22383643 0.80 MTNR1A (0.43) MTNR1ABRD4CREBBPSMYD3NPC1
SCHEMBL19774297 0.78 MTNR1A (0.47) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL1736809 0.78 CREBBP (0.55) BRD4CREBBPEP300TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591369-B Phosphoramidite ligand and preparation method and application thereof 中国科学院大连化学物理研究所 2024-05-10 CN disclosed
CN-114591369-A Phosphoramidite ligand and preparation method and application thereof 中国科学院大连化学物理研究所 2022-06-07 CN disclosed
CN-109336887-B Benzimidazole chiral heterocyclic compound and preparation method and application thereof 中山大学 2021-12-17 CN disclosed
CN-109575060-B Synthesis of spiro bisboron catalyst and application of spiro bisboron catalyst in hydrogenation reaction 南开大学 2020-11-17 CN disclosed
US-10565015-B2 Spiroketal-based C2-symmetric scaffold for asymmetric catalysis THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-02-18 US disclosed
US-20190084995-A1 Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2019-03-21 US disclosed
CN-109336887-A A kind of benzimidazole and chiral heterocycle class compound and its preparation method and application 中山大学 2019-02-15 CN disclosed
WO-2015040424-A1 TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS VERNALIS (R&D) LIMITED (GB) 2015-03-26 WO disclosed
WO-2015040424-A1 TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS VERNALIS (R&D) LIMITED (GB) 2015-03-26 WO disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-20090111760-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-04-30 US disclosed
EP-1824869-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-08-29 EP disclosed
WO-2006050941-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111760-A1 MACROLONE COMPOUNDS CYP51A1, MRPL21, MYD88 MTNR1A 3171/4885BRD4 2030/4885CREBBP 3384/4885
US-10565015-B2 Spiroketal-based C2-symmetric scaffold for asymmetric catalysis PKD2, OPA1, PKD1 MTNR1A 2780/4885BRD4 2706/4885CREBBP 4577/4885
US-20190084995-A1 Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis PKD2, OPA1, PKD1 MTNR1A 2780/4885BRD4 2706/4885CREBBP 4577/4885
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 MTNR1A 256/4885BRD4 505/4885CREBBP 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.